Comparison of endometrial carcinoma coexisting with and without endometrial hyperplasia.
OBJECTIVE
It has been reported that endometrial carcinoma has two pathogenic types; one with and the other without endometrial hyperplasia. The present study was done to clarify whether this was true in our series of a large number of Japanese patients.


METHODS
Three hundred and twenty-eight patients with endometrial carcinoma were classified into two groups, one coexisting endometrial hyperplasia (group 1; 182 cases) and the other having normal endometrium without endometrial hyperplasia (group 2; 107 cases). The clinical and pathological observations of the two groups were compared.


RESULTS
The ages of the patients were significantly lower in group 1 (30-83; mean 50.7) than in group 2 (34-81; mean, 57.2). The incidence of the carcinoma with invasion limited to less than 1/3 of the myometrium, with surgical stage I, lower grade endometrioid type and higher levels of progesterone receptor, and without lymph node metastasis were significantly higher in group 1 than in group 2. The cumulative survival rate for stage I was also significantly higher in group 1 patients.


CONCLUSIONS
A significant difference was found between groups 1 and 2 in age distribution, degree of progress and pathological observations. Stage I patients in the former group had a better prognostic than the latter.
Ohkawara
S
S
Department of Obstetrics and Gynecology, School of Medicine, Kitasato University, Japan.
Jobo
T
T
Sato
R
R
Kuramoto
H
H
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D018269:Carcinoma, Endometrioid / Q000150:complications* / Q000401:mortality / Q000473:pathology; D004714:Endometrial Hyperplasia / Q000150:complications* / Q000401:mortality / Q000473:pathology; D016889:Endometrial Neoplasms / Q000150:complications* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016019:Survival Analysis
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone